Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus

Behavioural Pharmacology

Volumn 11, Issue 3-4, 2000, Pages 269-278

  Al Amin, H A ^a,b   Weinberger, D R ^a   Lipska, B K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

AMPA antagonist; Animal model; Behavior; Dizocilpine; Hippocampus; LY293558; Neuroleptics; Rat; Schizophrenia

Indexed keywords

AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CLOZAPINE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL MODEL; ARTICLE; BRAIN DEVELOPMENT; BRAIN INJURY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOPAMINERGIC SYSTEM; DRUG EFFECT; HIPPOCAMPUS; HYPERACTIVITY; MALE; NONHUMAN; RAT; SCHIZOPHRENIA; STEREOTYPY;

EID: 0033947809     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200006000-00010     Document Type: Article

References (82)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554.
2. Amaral DG, Witter MP (1995). Hippocampal formation. In: The Rat Nerrous System. 2nd ed. Paxinos G (editor). Sydney: Academic Press, pp. 443-493.
3. Becker A, Grecksch G, Bernstein H-G, Hollt V, Bogerts B (1999). Social behavior in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144:333-338.
4. Behrens S, Gattaz WF (1992). MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J Neural Transm Gen Sect 90:219-224.
5. Black MD, Lister S, Hitchcock JM, Giersbergen P, Sorensen SM (1998). Neonatal hippocampal lesion model of schizophrenia in rats: sex differences and persistence of effects into maturity. Drug Dev Res 43:206-213.
6. Brake WG, Sullivan RM, Flores G, Srivastava L, Gratton A (1999). Neonatal ventral hippocampal lesions attenuate the nucleus accumbens dopamine response to stress: an electrochemical study in the rat. Brain Res 831:25-32.
7. Bubster M, Keseberg U, Notz PK, Schmidt WJ (1992). Differential behavioral and neurochemical effects of competitive and noncompetitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75-82.
8. Carlsson M, Carlsson A (1989). The NMDA antagonist MK801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221-226.
9. Carlsson M, Svensson A (1990). Interfering with glutamatergic neurotransission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol Biochem Behav 36:45-50.
10. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989). Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653-661.
11. Chambers RA, Moore J, McEvoy JP, Levin ED (1996). Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 15:587-594.
12. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982). Central sympathomimetic activity of (±)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cycloheptenn-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:134-145.
13. Dall'Olio R, Gandolfi O, Montanaro N (1992). Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology 107:591-594.
14. Davies BM, Beech HR (1960). The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Mental Sci 106:9912-9924.
15. Druhan JP, Rajabi H, Stewart J (1996). MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens. Synapse 24:135-146.
16. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 16:2020-2026.
17. Fontana DJ, Post RM, Pert A (1993). Conditioned increases in mesolimbic dopamine overflow by stimuli associated with cocaine. Brain Res 629:31-39.
18. Freed WJ, Weinberger DR, Bing LA, Wyatt RJ (1980). Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology (Berl) 71:291-297.
19. French ED (1986). Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the rat. Neuropharmacology 25:241-248.
20. French ED, Ceci A (1990). Noncompetitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci Lett 119:159-162.
21. French ED, Vantini G (1984). Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens'. comparisons with other psychostimulants. Psychopharmacology 82:83-88.
22. Gasbarri A, Verney C, Innocenzi R, Campana E, Pacitti C (1994). Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res 668:71-79.
23. Gattaz WF, Schummer B, Behrens S (1994). Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect 96:227-232.
24. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
25. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B (1999). Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20:525-532.
26. Hauber W, Andersen R (1993). The non-NMDA glutamate receptor antagonist GYKI 5266 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch Pharmacol 348:486-490.
27. Hauber W, Schmidt WJ (1990). The NMDA antagonist dizocilpine (MK-801) reverses haloperidol-induced movement initiation deficits. Behav Brain Res 41:161-166.
28. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990). NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555-556.
29. Itil T, Keskiner A, Kiremitci N, Holden JMC (1967). Effect of phencyclidine in chronic schizophrenics. Can J Psychiat 12:209-212.
30. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
31. Jay TM, Witter MP (1991). Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgarisleucoagglutinin. J Comp Neural 313:574-586.
32. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
33. Jentsch JD, Taylor JR, Roth RH (1998). Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress-and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19:105-113.
34. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG (1998). Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
35. Karreman M, Westerink BHC, Moghaddam B (1996). Excitatory amino acid receptors in the ventral tegmental area regulate dopamine release in the ventral striatum. J Neurochem 67:601-607.
36. Kashihara K, Hamamura T, Okumura K, Otsuki S (1990). Effect of MK-801 on endogenous dopamine release in vivo. Brain Res 528:80-82.
37. Knable MB, Murray AM, Lipska BK, Karoum F, Weinberger DR (1994). D2/D3 and D4 receptor densities are not altered in rats with neonatal hipppocampal damage. Soc Neurosci Abstract 513.3.
38. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD et al. (1994). Subanesthetic effects of noncompetitive NMDA receptor antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiat 51:199-214.
39. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869-872.
40. Lapin IP, Rogawski MA (1992). Muscarinic antagonists attenuate dizocilpine-induced hypermotility in mice. Life Sci 50:59-64.
41. Liljequist S, Ossowska K, Grabowska-Anden M, Anden N (1991). Effect of the NMDA antagonist, MK-801, on locomotor activity and the metabolism of dopamine in various brain areas in mice. Eur J Pharmacol 195:55-61.
42. Lillrank SM, Lipska BK, Kolachana B, Weinberger DR (1999). Altered levels of extracellular dopamine and 5-HIAA after restraint stress and amphetamine in rats with neonatal ventral hippocampal damage. An in vivo microdialysis study in awake rats. J Neur Transm 106:183-196.
43. Lipska BK, Weinberger DR (1993). Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced Stereotypic behaviors in the rat. Dev Brain Res 75:213-222.
44. Lipska BK, Weinberger DR (1994a). Subchronic treatment with haloperidol or clozapine in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology 10:199-205.
45. Lipska BK, Weinberger DR (1994b). Gonadectomy does not prevent novelty-or drug-induced hyperresponsiveness in rats with neonatal excitotoxic hippocampal damage. Dev Brain Res 78:253-258.
46. Lipska BK, Weinberger DR (1995). Genetic variation in vulnerability to the behavioral effects of neonatal hippocampal damage in rats. Proc Natl Acad Sci USA 92:8906-8910.
47. Lipska BK, Jaskiw GE, Weinberger DR (1993). Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology 9:67-75.
48. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995a). Neonatal excitotoxic hippocampal damage in rats causes postpubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122:35-43.
49. Lipska BK, Chrapusta SJ, Egan ME, Weinberger DR (1995b). Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild chronic stress and haloperidol treatment. Synapse 20:125-130.
50. Lipska BK, Al-Amin HA, Khaing ZZ, Lerman DN, Lillrank SM, Weinberger DR (1997). Effects of acute and chronic neuroleptic treatment on expression of D2 and D3 receptors, neurotensin and enkephalin mRNA in rats with neonatal lesions of the ventral hippocampus. Soc Neuroci Abstract 23:1361.
51. Lipska BK, Khaing ZZ, Lerman DN, Akil M, Weinberger DR (1999). Regulation of tyrosine hydroxylase and dopamine transporter mRNA by antipsychotic drugs in a rat model of schizophrenia. Soc Neurosci Abstract 25:162.
52. Loscher W, Honack D (1992). The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacology 215:199-208.
53. Loscher W, Annies R, Honack D (1991). The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128:191-194.
54. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959). Study of a new schizophrenic-like drug: Sernyl. Arch Neural Psychiat 81:363-369.
55. Maj J, Rogoz Z, Skuza G (1991). Locomotor hyperactivity induced by MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Pol J Pharmacol Pharm 43:449-458.
56. Mele A, Thomas DN, Pert A (1998). Different neural mechanisms underlie dizocilpine maleate-and dopamine agonist-induced locomotor activity. Neuroscience 82:43-58.
57. Miller DW, Abercrombie ED (1996). Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40:57-62.
58. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281(5381): 1349-1352.
59. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
60. Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N (1996). Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 54:565-573.
61. Ogren SO, Goldstein M (1994). Phencyclidine-and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11:167-177.
62. O'Neill MF, Shaw G (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl) 145:237-250.
63. Sams-Dodd F (1996). Phencyclidine-induced stereotyped behavior and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 7:3-23.
64. Sams-Dodd F (1998). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19:18-25.
65. Sams-Dodd F, Lipska BK, Weinberger DR (1997). Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 132:303-310.
66. Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright A et al. (1995). In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34:1159-1168.
67. Sesack SR, Pickel VM (1990). In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527:266-279.
68. Sesack SR, Pickel VM (1992). Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neural 320:145-160.
69. Stine CD, Lu WX, Xue C-J, Wolf ME (1997). Cortical and subcortical glutamate receptor expression and glutamate transmission in a rat model of schizophrenia. Soc Neurosci Abstract 23:1928.
70. Svensson A, Pileblad E, Carlsson M (1991). A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm Gen Sect 85:117-129.
71. Taber MT, Das S, Fibiger HC (1995). Cortical regulation of subcortical dopamine release: Mediation via the ventral tegmental area. J Neurochem 65:1407-1410.
72. Takahata R, Moghaddam B (1998). Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem 71:1443-1449.
73. Tong ZY, Overton PG, Clark D (1996). Antagonism of NMDA receptors but not AMPA/kainate receptors blocks bursting in dopaminergic neurons induced by electrical stimulation of the prefrontal cortex. J Neural Transm 103:889-904.
74. Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379.
75. Wan RQ, Corbett R (1997). Enhancement of postsynaptic sensitivity to dopaminergic agonists induced by neonatal hippocampal lesions. Neuropsychopharmacology 16:259-268.
76. Wan R-Q, Giovanni A, Kafka SH, Corbett R (1996). Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies. Behav Brain Res 78:211-223.
77. Wan RQ, Hartman H, Corbett R (1998). Alteration of dopamine metabolites in CSF and behavioral impairments induced by neonatal hippocampal lesions. Physiol Behar 65:429-436.
78. Wedzony K, Klimek V, Golembiewska K (1993). MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res 622:325-329.
79. Weinberger DR, Lipska BK (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: In search of common ground. Schiz Res 16:87-110.
80. Whitton PS, Biggs CS, Pearce BR, Fowler LJ (1992). Regional effects of MK-801 on dopamine and its metabolites studied by in vivo microdialysis. Neurosci Lett 142:5-8.
81. Willins DL, Narayanan S, Wallace LJ, Uretsky NJ (1993). The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharm Biochem Behav 46:881-887.
82. Wolf ME, White FJ, Hu X-T (1993). Behavioural sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav Pharmacol 4:429-442.